Liu J, Burris H, Wang JS, et al. - Researchers herein investigated the safety, tolerability, pharmacokinetics, and preliminary activity of DMUC4064A in cases with platinum-resistant OC.

• Poor response rates have been recorded in treatment of platinum-resistant ovarian cancer.

• Considering the wider therapeutic index of antibody-drug conjugates in comparison to small molecules, researchers synthesized DMUC4064A, an anti-MUC16 THIOMAB-drug conjugate, to have a more homogenous payload than ADCs.

• Patients were administered DMUC4064A once every 3 weeks in 1.0–5.6 mg/kg dose escalation cohorts; this was followed by cohort expansion at the recommended phase 2 dose (RP2D).

• A total of 65 enrolled patients received a median of 5 cycles (range 1–20) of DMUC4064.

• DMUC4064A demonstrated a tolerable safety profile, along with preliminary activity in 25% of patients; this indicates that it has encouraging efficacy in the indication of platinum-resistant OC.